Sanofi’s investment strategy for transitioning to a pure biopharma
In October 2023, Sanofi announced plans to separate its consumer health unit in 2024. Sanofi’s consumer health division, with flagship products like Doliprane and Allegra, has been a reliable contributor to the company’s revenue. However, as CEO Paul Hudson implements his “play to win” strategy, these products, while strong, do not align with Sanofi’s evolving vision to lead in high-impact, high-growth areas like oncology, immunology, and vaccines. The key to Sanofi becoming a pure biopharma player: investment.
A year later, the French company announced the divestment of a 50% controlling stake in its consumer health division, Opella, to U.S. private equity firm Clayton Dubilier & Rice (CD&R) in a deal valued at approximately…
